Kadima T A, Weiner J H
Department of Biochemistry, University of Alberta, Edmonton, Canada.
Antimicrob Agents Chemother. 1997 Oct;41(10):2177-83. doi: 10.1128/AAC.41.10.2177.
Resistance to piperacillin in several isolates of Citrobacter freundii and Enterobacter cloacae was investigated and confirmed to occur at a frequency of 10(-7) to 10(-6). Development of resistance to piperacillin was significantly suppressed by tazobactam but not by clavulanic acid. To elucidate the mechanism by which resistance suppression occurs, the effect of piperacillin plus tazobactam on the induction of AmpC beta-lactamase was analyzed by monitoring the beta-galactosidase activity of an inducible ampC-lacZ gene fusion in Escherichia coli. The combination exerted no inhibitory effect on AmpC beta-lactamase induction. Tazobactam also had no effect on the accumulation of a key intermediate in the AmpC beta-lactamase induction pathway, 1,6-anhydromurotripeptide, in an ampD mutant strain of E. coli. However, the addition of tazobactam to liquid cultures of E. cloacae 40001 in the presence of piperacillin at four times the MIC caused a delay in the recovery of the culture to piperacillin-induced stress. At 16 times the MIC, a complete suppression of regrowth occurred. Analysis of culture viability on piperacillin plates showed that the culture recovery was due to growth by moderately resistant mutants preexisting in the cell population, which at 16 times the MIC became susceptible to the combination. Evidence from the kinetics of inhibition of the E. cloacae 40001 AmpC beta-lactamase by clavulanic acid, sulbactam, and tazobactam and from the effects of these drugs on the frequency of resistance to piperacillin suggests that the suppressive effect of tazobactam on the appearance of resistance is primarily mediated by the beta-lactamase inhibitory activity.
对弗氏柠檬酸杆菌和阴沟肠杆菌的几种分离株对哌拉西林的耐药性进行了研究,证实其发生频率为10^(-7)至10^(-6)。他唑巴坦可显著抑制对哌拉西林耐药性的产生,而克拉维酸则无此作用。为阐明耐药性抑制发生的机制,通过监测大肠杆菌中可诱导的ampC-lacZ基因融合体的β-半乳糖苷酶活性,分析了哌拉西林加他唑巴坦对AmpCβ-内酰胺酶诱导的影响。该组合对AmpCβ-内酰胺酶的诱导没有抑制作用。他唑巴坦对大肠杆菌ampD突变株中AmpCβ-内酰胺酶诱导途径中的关键中间体1,6-脱水 Mur 三肽的积累也没有影响。然而,在四倍MIC的哌拉西林存在下,向阴沟肠杆菌40001的液体培养物中添加他唑巴坦会导致培养物从哌拉西林诱导的应激中恢复延迟。在16倍MIC时,完全抑制了再生长。对哌拉西林平板上培养物活力的分析表明,培养物的恢复是由于细胞群体中预先存在的中度耐药突变体的生长,这些突变体在16倍MIC时对该组合变得敏感。克拉维酸、舒巴坦和他唑巴坦对阴沟肠杆菌40001 AmpCβ-内酰胺酶抑制动力学的证据以及这些药物对哌拉西林耐药频率的影响表明,他唑巴坦对耐药性出现的抑制作用主要由β-内酰胺酶抑制活性介导。